Systemic lupus erythematosus (SLE) is a complex multi-organ autoimmune disease marked by the production of autoantibodies against nuclear structures, formation of immune complexes, and chronic inflammation triggered by their tissular deposition. SLE is characterized by alternating periods of relapse and remission and each flare has the potential to cause new organ damage related to either the disease process or the medication toxicity. Despite remarkable progress across its multiple domains, SLE is still an area with many unmet needs, calling for innovative and practical solutions. The efforts of the drug development programme in lupus have led to considerable growth in the last decade, owing to the approval of belimumab, anifrolumab, and voclosporin. The increasing understanding of the pathogenesis of the disease has enabled the exploration of novel therapeutic strategies. New discoveries in the intricate cytokine kaleidoscope of lupus have made the concept of targeted therapy an attractive and promising research focus. JAK inhibitors are oral targeted therapies approved for a wide variety of diseases across the Rheumatology, Gastroenterology, Dermatology, and Haematology fields. Multiple JAKis are currently being investigated in SLE. This paper aims to summarize existing data coming from both clinical trials and case reports regarding the use of JAK inhibitors in SLE.
PieterseEvan der VlagJ. Breaking immunological tolerance in systemic lupus erythematosus. Front Immunol2014; 5: 164.
2.
SutantoHYuliasihY. Disentangling the pathogenesis of systemic lupus erythematosus: close ties between immunological, genetic and environmental factors. Medicina2023; 59(1033): 1033.
3.
PigaMArnaudL. The main challenges in systemic lupus erythematosus: where do we stand?J Clin Med2021; 10(2): 243.
4.
Gómez-PuertaJ. Real-world data on anifrolumab, the new kid on the block in lupus. Rheumatology2024: 63: 2325–2327.
5.
RussellMStovinCAlveynE, et al.JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications. Ann Rheum Dis2023; 82(8): 1059–1067.
BennettLPaluckaAArceE, et al.Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med2003; 197(6): 711–723.
8.
RönnblomLLeonardD. Interferon pathway in SLE: one key to unlocking the mystery of the disease. Lupus Sci Med2019; 6(1): e000270.
9.
Gómez-BañuelosEGoldmanDAndradeV, et al.Uncoupling interferons and the interferon signature explains clinical and transcriptional subsets in SLE. Cell Rep Med2024; 5(5): 101569.
10.
WongCLitLTamL, et al.Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol2008; 127(3): 385–393.
11.
PanLLuMWangJ, et al.Immunological pathogenesis and treatment of systemic lupus erythematosus. World J Pediatr2020; 16(1): 19–30.
12.
ChyuanITzengHChenJ. Signaling pathways of type I and type III interferons and targeted therapies in systemic lupus erythematosus. Cells2019; 8(9): 963.
13.
SirobhushanamSLazarSKahlenbergJ. Interferons in systemic lupus erythematosus. Rheum Dis Clin N Am2021; 47(3): 297–315.
14.
RönnblomLAlmG. A pivotal role for the natural interferon α–producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus. J Exp Med2001; 194(12): F59–F63.
15.
SchogginsJ. Interferon-stimulated genes: what do they all do?Annu Rev Virol2019; 6(1): 567–584.
16.
LeeAAshkarA. The dual nature of type I and type II interferons. Front Immunol2018; 9: 2061.
17.
FuXKesslerDVealsS, et al.ISGF3, the transcriptional activator induced by interferon alpha, consists of multiple interacting polypeptide chains. Proc Natl Acad Sci U S A1990; 87(21): 8555–8559.
18.
Castelo-SoccioLKimHGadinaM, et al.Protein kinases: drug targets for immunological disorders. Nat Rev Immunol2023; 23(12): 787–806.
19.
BonelliMKerschbaumerAKastratiK, et al.Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story. Ann Rheum Dis2024; 83(2): 139–160.
20.
CollottaDFranchinaMCarlucciV, et al.Recent advances in JAK inhibitors for the treatment of metabolic syndrome. Front Pharmacol2023; 14: 1245535.
21.
YanQChenWSongH, et al.Tofacitinib ameliorates lupus through suppression of T cell activation mediated by TGF-beta type I receptor. Front Immunol2021; 12: 675542.
22.
YamamotoMYokoyamaYShimizuY, et al.Tofacitinib can decrease anti-DNA antibody titers in inactive systemic lupus erythematosus complicated by rheumatoid arthritis. Mod Rheumatol2016; 26(4): 633–634.
23.
ApaydınHErtenŞ. Tofacitinib-induced subacute cutaneous lupus erythematosus in a patient with rheumatoid arthritis. Mod Rheumatol Case Rep2021; 5(2): 254–658.
24.
LeeJParkYJangS, et al.Baricitinib attenuates autoimmune phenotype and podocyte injury in a murine model of systemic lupus erythematosus. Front Immunol2021; 12: 704526.
25.
WallaceDFurieRTanakaY, et al.Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet2018; 392(10143): 222–231.
26.
DörnerTvan VollenhovenRDoriaA, et al.Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial. Arthritis Res Ther2022; 24(1): 112.
27.
MerrillJTanakaYD’cruzD, et al.OP0139 efficacy and safety of ABBV-599 high dose (elsubrutinib 60 MG and upadacitinib 30 MG) and upadacitinib monotherapy for the treatment of systemic lupus erythematosus: a phase 2, double-blind, placebo-controlled trial. Ann Rheum Dis2023; 82: 91–92.
28.
GaudreauMFannJFriedmanA, et al. Treatment with upadacitinib in patients with systemic lupus erythematosus results in the inhibition of B-Cell–related biomarkers: analysis of the M19-130 (SLEek) phase 2 study [abstract]. Arthritis Rheumatol. 2023; 75(9): 2940.
29.
PohlmeyerCCuiZHanP, et al.AB0484 Monotherapy with filgotinib, a jak1-selective inhibitor, reduces disease severity and alters immune cell subsets in the nzb/w f1 murine model of lupus. Ann Rheum Dis2018; 77: 1403.
30.
BakerMChaichianYGenoveseM, et al.Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy. RMD Open2020; 6(3): e001490.
31.
WerthVFleischmannRRobernM, et al.Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study. Rheumatology2022; 61(6): 2413–2423.
32.
KahlLPatelJLaytonM, et al.Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus. Lupus2016; 25(13): 1420–1430.
33.
MorandEMerolaJTanakaY, et al.TYK2: an emerging therapeutic target in rheumatic disease. Nat Rev Rheumatol2024; 20(4): 232–240.
34.
MorandEPikeMMerrillJ, et al.Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol2023; 75(2): 242–252.
JimenezPSofenHBissonnetteR, et al.Oral spleen tyrosine kinase/Janus Kinase inhibitor gusacitinib for the treatment of chronic hand eczema: results of a randomized phase 2 study. J Am Acad Dermatol2023; 89(2): 235–242.
37.
HasniSGuptaSDavisM, et al.Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus. Nat Commun2021; 12(1): 3391.
38.
AlsukaitSLearnedCRosmarinD. Open-label phase 2 pilot study of oral tofacitinib in adult subjects with Discoid Lupus Erythematosus (DLE). J Drugs Dermatol JDD2023; 22(4): 425–427.
39.
MorandEVitalEPetriM, et al.Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I). Lancet2023; 401(10381): 1001–1010.
40.
PetriMBruceIDörnerT, et al.Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II). Lancet2023; 401(10381): 1011–1019.
41.
MorandESmolenJPetriM, et al.Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysis. RMD Open2023; 9(3): e003302.
42.
OwenKBrockwellNParkerB. JAK-STAT signaling: a double-edged sword of immune regulation and cancer progression. Cancers2019; 11(12): 2002.
43.
YtterbergSBhattDMikulsT, et al.Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med2022; 386(4): 316–326.
44.
SalinasCLouderAPolinskiJ, et al.Evaluation of VTE, MACE, and serious infections among patients with RA treated with baricitinib compared to TNFi: a multi-database study of patients in routine care using disease registries and claims databases. Rheumatol Ther2023; 10(1): 201–223.
45.
LiuYKaplanM. Cardiovascular disease in systemic lupus erythematosus: an update. Curr Opin Rheumatol2018; 30(5): 441–448.
46.
MoschettiLPiantoniSVizzardiE, et al.Endothelial dysfunction in systemic lupus erythematosus and systemic sclerosis: a common trigger for different microvascular diseases. Front Med2022; 9: 849086.
47.
EdwardsCLianTBadshaH, et al.Hospitalization of individuals with systemic lupus erythematosus: characteristics and predictors of outcome. Lupus2003; 12(9): 672–676.
48.
KunzlerATsokosG. Infections in patients with systemic lupus erythematosus: the contribution of primary immune defects versus treatment-induced immunosuppression. Eur J Rheumatol2023; 10(4): 148–158.
49.
CerveraRSerranoRPons-EstelG, et al.Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis2015; 74(6): 1011–1018.
50.
BhoelanSBorjas HowardJTichelaarV, et al.Recurrence risk of venous thromboembolism associated with systemic lupus erythematosus: a retrospective cohort study. Res Pract Thromb Haemost2022; 6(8): e12839.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
